Navigation Links
Human Pheromone Sciences Announces Fourth Quarter and Full Year Results
Date:3/27/2009

SAN JOSE, Calif., March 27 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") today announced results for the three months and the year ended December 31, 2008. For the three months ended December 31, 2008, net revenue was $228,000, representing a 41% decrease from revenues of $389,000 in the prior year period, and resulted in net loss of $(58,000) ($(0.01) per share) as compared with net income of $38,000 ($0.01 per share) for the same period in 2007. For the full year, net revenues of $992,000, were 23% less than revenues of $1,291,000 generated in the prior year. The net loss in the current year of $239,000 ($0.06 per share) was $223,000 higher than the $16,000 loss ($.00 per share) recorded for the full year of 2007. Net cash utilized for the full year of 2008 was $530,000, less than a 5% increase from the $501,000 utilized in the year 2007.

"The revenue reduction in the fourth quarter and the full year was attributable to a significant reduction in purchases by our largest and first multinational licensee of pheromones. Over the past 10 years we have been principally dependent on purchases by this customer for revenue generation. Total product revenues decreased by approximately 50% from this customer in 2008," a spokesperson noted.

"Over the past couple of years, we developed a multi-faceted program to be less dependent on any one customer, seek additional licensees in the U.S. and abroad for our original pheromone technologies, complete scientific validation on our most promising mood-enhancing compound and present the results to consumer marketers. With respect to the first strategic imperative, during 2008, licensing revenue increased to $604,000, a 15% growth from the prior year, primarily attributable to new agreement with a multinational corporation. Discussions are ongoing with potential licensees and we are also in discussions to broaden the channels of distribution for our initial pheromone compounds. With respect to the second area of focus, the discovery and patented protection of new mood-enhancing compounds, the Company filed a final U.S. Patent Application and a European filing for a compound that has shown significantly enhanced positive feelings and emotions in both men and women. We are currently presenting the results of the human studies on ER 303 to several multinational consumer products companies. In addition, the Company completed initial toxicology testing and initial human response studies on another compound for women, and we have identified and selected six additional compounds that have shown promise in initial laboratory studies."

"We believe that focus on these basic strategic imperatives will lessen our dependence on the purchasing pattern of one large customer, and ensure balanced growth in revenue and an expanded technology and customer base, without major capital investment," the spokesman further stated.

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of-concept products included prestige-priced fragrances and toiletries and environmental products sold under the REALM(R), innerREALM(R) and EROX(R) trademarks. These products, and its Natural Attraction(R) product line, contain mood-enhancing synthesized human pheromones covered under U.S. and foreign patents. The Company also licenses its proprietary technology to other companies for inclusion in their products for direct sale to the consumer. Scientific and consumer studies have shown that the Company's human pheromones positively impact on the moods, attitudes and emotions of wearers. Further information is available online at www.erox.com.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

                          HUMAN PHEROMONE SCIENCES, INC.
                            Condensed Balance Sheets
                             (Dollars in thousands)

                                            December 31,          December 31,
                                               2008                  2007

    Assets

    Cash and cash equivalents             $         907       $         1,437
    Accounts receivable                              52                   194
    Inventories, net                                 39                    25
    Other current assets                             58                    40
    Property and equipment, net                       2                     3
                                          -------------       ---------------

    Total                                 $       1,058       $         1,699
                                          =============       ===============

    Liabilities and Shareholders' Equity

    Accounts payable                      $          19       $           28
    Other current liabilities                       131                  141
    Deferred income - current                       297                  518
    Deferred income - non-current                   324                  566
    Common stock                                 21,043               20,963
    Accumulated deficit                         (20,756)             (20,517)
                                          -------------       ---------------

    Total                                 $       1,058       $        1,699
                                          =============       ===============



                          HUMAN PHEROMONE SCIENCES, INC.
                        Condensed Statements of Operations
                  (Dollars in thousands, except per-share data)

                                    Three months                 Year
                                 ended December 31,        ended December 31,
                                 2008         2007         2008         2007

    Net revenues               $  228       $  389       $  992     $  1,291

    Cost of goods sold             82           99          322          376
    Research and development       14           11           47           49
    Selling, general and
     administrative               193          256          889          942
                               ------       ------       ------     --------

    Income (loss) from
     operations                   (61)          23         (266)         (76)

    Other income                    5           15           30           65
                               ------       ------       ------     --------

    Income (loss) before
     provision for income taxes   (56)          38         (236)         (11)

    Provision for Income taxes      2            -            3            5
                               ------       ------       ------     --------

    Net income (loss)          $  (58)      $   38       $ (239)    $    (16)
                               ======       ======       ======     ========



    Net income (loss)
     per share -

         Basic                 $(0.01)      $ 0.01       $(0.06)    $  (0.00)
         Fully diluted         $(0.01)      $ 0.01       $(0.06)    $  (0.00)

    Weighted average number
     of shares -

         Basic                  4,152        4,152        4,152        4,152
         Fully diluted          4,152        4,852        4,152        4,152


    Net income (loss) per share is based on the weighted average number of
    common shares and common equivalents outstanding during each period.
    Certain common stock equivalents are excluded when their effect would be
    anti-dilutive.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Federal funding gap cited for research on human health impacts due to climate change
2. Human papillomavirus genotype distribution in New Mexico cervical cancers
3. Human Brain Works Between Order and Chaos
4. The human tragedy of denying AIDS
5. Research Finds Popular Household Pets Transmit Dangerous Parasites to Humans
6. Chicago's Own Hacker Con Set for May, Teaches Human Hacking to Corporations
7. University of Pennsylvania researchers find that the unexpected is a key to human learning
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen Conference
9. The Heart Foundation Honors Celebrity Chef Wolfgang Puck With The Steven S. Cohen Humanitarian Award
10. Beaumont Launches 1st U.S. Adult Human Stem Cell Study for Stress Urinary Incontinence
11. Global War on Drugs Takes Devastating Toll on Human Lives, Advocates Say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , ... May 31, 2016 , ... Phynd Technologies, Inc. ... GA; Houston Methodist – Houston, TX and Shore Medical Center – Somers Point, NJ. ... three different, leading EHR solutions, demonstrating the breadth of Phynd’s solution and its interoperability. ...
(Date:5/31/2016)... ... , ... In a recent interview on The Greenburgh Report radio show hosted ... WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening ... maelstrom.” , During the interview with Mr. Feiner that aired on May 7, ...
(Date:5/31/2016)... ... ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree from ... where he graduated in the top ten percentile of his class. Dr. Ditta has ... has been a member in good standing for thirty years in the American Dental ...
(Date:5/31/2016)... ... May 31, 2016 , ... To meet ... to the healthcare industry, The University of Scranton is adding a Certificate in ... to a career in rapidly growing field of healthcare information. , Healthcare ...
(Date:5/31/2016)... ... May 31, 2016 , ... Super Powder, a supplement produced ... the go individuals and dedicated athletes, continues to transform the nutritional supplement industry by ... pea and milk protein, branched-chain amino acids (BCAA), alkaline minerals, wheat grass, digestive enzymes, ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... , May 30, 2016 ... titled, "Advanced (3D/4D) Visualization Systems Market - Global Industry ... 2024." According to the report, the global advanced (3D/4D) ... in 2015 and is anticipated to expand at a ... US$ 3.2 Bn in 2024. Advanced (3D/4D) ...
(Date:5/30/2016)... -- - DCGI grants limited approval to market Stempeucel® ... - Stempeucel® becomes 5th off-the-shelf Stem cell product to be ... - Buerger,s Disease (also known as Thromboangiitis Obliterans) is a major ... - Prevalence of Buerger,s Disease is estimated to be ... persons in the European Community & USA ...
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
Breaking Medicine Technology: